Understanding the mercury-based preservative: what it is, how it works in the body, and why it remains controversial.
Thimerosal is a mercury-based preservative that has been used in some vaccines since the 1930s. It has been the subject of sustained public concern, particularly regarding a possible link to autism in children - a link that extensive scientific research has not supported. This page presents the chemistry, the safety evidence, and the history of the public debate so readers can evaluate the full picture.
Note: Looking for the public controversy and policy history? See Section 4 below.
Thimerosal (sodium ethylmercurithiosalicylate) is an organomercury compound used as a preservative to prevent bacterial and fungal contamination in multi-dose vaccine vials. It has been used in vaccines since the 1930s and in other pharmaceutical products including some topical medications and contact lens solutions.
The central distinction in understanding thimerosal is the difference between its metabolite, ethylmercury, and methylmercury - the form found in some fish and the environment. These are chemically different compounds with different properties in the body.
In the United States, thimerosal was removed from or reduced to trace amounts in all routinely recommended childhood vaccines between 1999 and 2001. This means children receiving vaccines today are not exposed to thimerosal through routine immunization schedules.
Thimerosal remains in some multi-dose influenza vaccine vials. However, thimerosal-free flu vaccine options are widely available for those who prefer them. Globally, thimerosal remains in wider use in multi-dose vaccine programs, particularly in low- and middle-income countries where single-dose vials are not practical.
All humans are exposed to trace amounts of mercury through food, water, and air. Methylmercury in fish is the most common dietary source of mercury exposure for most people. This background exposure is an important context for understanding relative mercury doses from vaccines.
A thimerosal-containing vaccine dose contains approximately 25 micrograms of ethylmercury. A typical serving of canned tuna contains approximately 40-80 micrograms of methylmercury - higher than a single vaccine dose.
However, direct comparison is complicated by the difference in chemical form. The key distinction is that ethylmercury is cleared more rapidly than methylmercury, reducing the potential for accumulation.
Federal guidelines for mercury exposure set by the EPA, FDA, and ATSDR were established based on methylmercury, not ethylmercury. In 1999, these methylmercury guidelines were applied as a precautionary measure to estimate safe levels of ethylmercury exposure from vaccines.
Subsequent research has shown that this precautionary application overstated the risk, since ethylmercury is metabolized and cleared differently than methylmercury. This does not mean the precaution was unreasonable at the time - it reflects how regulatory bodies apply conservative approaches when scientific uncertainty exists.
In the late 1990s, concerns were raised that cumulative mercury exposure from childhood vaccines might exceed federal safety guidelines. This coincided with rising autism diagnosis rates, leading some researchers, advocates, and parents to hypothesize a causal link between thimerosal and autism.
In July 1999, the American Academy of Pediatrics (AAP) and U.S. Public Health Service jointly recommended removing thimerosal from childhood vaccines as a precautionary measure. This was not a determination that harm had been proven - it was a step taken to reduce mercury exposure while further studies were conducted.
By 2001, thimerosal had been removed from all routinely recommended childhood vaccines, with the exception of some multi-dose influenza preparations. This represents one of the largest voluntary reformulations of a medical product in history.
Multiple large-scale epidemiological studies conducted in the United States, Denmark, United Kingdom, and other countries found no association between thimerosal-containing vaccines and autism or other neurodevelopmental disorders.
An important observation: autism diagnosis rates continued to rise after thimerosal was removed from childhood vaccines. If thimerosal were a causal factor, researchers would expect to see rates decline following removal - but they did not.
Major health organizations including the World Health Organization (WHO), FDA, CDC, AAP, the Institute of Medicine (now the National Academy of Medicine), and the European Medicines Agency (EMA) have all concluded that the evidence does not support a causal link between thimerosal and autism.
For many families, concerns about thimerosal connect to broader questions about trust in pharmaceutical companies, regulatory transparency, and the experience of parents seeking explanations for their children's developmental challenges.
These concerns are not irrational - they reflect real questions about institutional accountability and parental advocacy. However, the scientific evidence on the specific question of thimerosal and autism has been extensively studied and does not support a causal connection.
In June 2025, ACIP voted to recommend removal of thimerosal from all vaccines. This recommendation reflects ongoing public pressure rather than new safety evidence. WHO continues to support thimerosal use in multi-dose vaccine programs globally, noting that the benefits of preventing disease through accessible multi-dose vaccination outweigh the theoretical risks of trace thimerosal exposure.